Skip to main content
Strategic Partners A/S logo

Strategic Partners A/S — Investor Relations & Filings

Ticker · STRAP ISIN · DK0062502894 LEI · 54930025OZD2GGSQ7L42 CO Financial and insurance activities
Open in API
Filings indexed 501 across all filing types
Latest filing 2020-01-31 Share Issue/Capital Cha…
Country DK Denmark
Listing CO STRAP

About Strategic Partners A/S

https://www.strategic-partners.dk/

Strategic Partners A/S is an investment company that engages in strategic partnerships with businesses that have significant potential. The company's strategy involves taking an active ownership role to create value through its competencies. In addition to its primary focus, the firm may also invest in other equity interests and properties to generate returns. Formerly known as Orphazyme A/S, the company sold its biotechnology activities in May 2022. A new board and management team was appointed in May 2023, and the company officially adopted its new strategy, purpose, and name in October 2024.

Recent filings

Filing Released Lang Actions
Capital increase of 20,650 shares (equivalent to approximately 0.10% of the existing shares) in Orphazyme A/S as a result of an issue of bonus shares to KLSDC and UCLB
Share Issue/Capital Change Classification · 100% confidence The document is a company announcement regarding a capital increase through the issuance of 20,650 new bonus shares. It details the reason for the issuance (license agreement obligations), the impact on total share capital, and the expected listing date. This falls under the category of share issuance or capital changes.
2020-01-31 English
Capital increase of 20,650 shares (equivalent to approximately 0.10% of the existing shares) in Orphazyme A/S as a result of an issue of bonus shares to KLSDC and UCLB
Share Issue/Capital Change Classification · 100% confidence The document is a company announcement regarding a capital increase through the issuance of bonus shares. It details the specific number of shares issued (20,650), the recipients (KLSDC and UCLB), and the impact on the total share capital and voting rights. This falls under the category of 'Share Issue/Capital Change' (SHA), as it describes a specific corporate action involving the issuance of new shares.
2020-01-31 English
Reporting of transactions in Orphazyme’s shares made by persons discharging managerial responsibilities
Director's Dealing Classification · 100% confidence The document is a formal notification regarding share transactions made by a person discharging managerial responsibilities (the CEO, Kim Stratton). It explicitly cites the Market Abuse Regulation (MAR) article 19, which governs the reporting of insider/director dealings. The content provides specific details of the transaction, including the person's name, position, financial instrument, nature of the transaction (purchase), price, volume, and date. This aligns perfectly with the definition of a Director's Dealing (DIRS) filing.
2020-01-07 English
Director's Dealing 2020
Director's Dealing Classification · 100% confidence The document is titled "Reporting of transactions in Orphazyme's shares made by persons discharging managerial responsibilities" and explicitly states it is a notification pursuant to the Market Abuse Regulation article 19 regarding transactions (purchases) in the company's shares by the Chief Executive Officer (a person discharging managerial responsibilities). This directly corresponds to the definition of Director's Dealing (insider trades) filings. Filing Code: DIRS.
2020-01-07 English
Orphazyme announces US Early Access Program for Niemann-Pick disease Type C
Regulatory Filings Classification · 95% confidence The document is a company announcement from Orphazyme A/S regarding the launch of an Early Access Program for a drug. It is a short, news-style release (under 5,000 characters of core content) that functions as a general regulatory announcement. It does not fit into specific categories like 10-K, IR, or DIRS, and while it mentions an attachment, it is a standard corporate press release/regulatory filing.
2020-01-06 English
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is titled "Company announcement Orphazyme A/S" and details the immediate availability of an Early Access Program (EAP) for their drug arimoclomol in the US. It is a press release format announcing a specific operational/access update regarding a drug, not a comprehensive financial report (like 10-K or IR), a formal voting result (DVA), or a management change (MANG). While it relates to the company's operations, it is a specific, time-sensitive announcement that doesn't fit the defined categories for financial results (ER, IR), capital structure (CAP, SHA), or governance (CGR, DEF 14A). Since it is a general company announcement regarding a specific operational/access development that doesn't fit the more specific categories, the most appropriate fallback is Regulatory Filings (RNS), as it is a formal communication to the market.
2020-01-06 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.